Rifaximin、Lactulose
Phase 2Small molecule
Rifaximin、Lactulose is one of 2 small molecule programs targeting Hepatic Encephalopathy. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
1
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
2 competitors in Fecal Microbiota Transplantation
#DrugCompanyPhaseTrials
1Tecentriq
RochePhase 2
Rifaximin、Lactulose
AAir Force Military Medical University, China
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Fecal Microbiota Transplantation1 trial
Evaluation of the Outcome of Fecal Microbiota Transplantation
Not yet recruiting·—·Phase 1/2·NCT07454408·40 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Rifaximin、Lactulose. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details